Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 1
2006 1
2007 2
2011 3
2012 1
2013 1
2014 6
2015 2
2016 6
2017 4
2018 5
2019 2
2020 2
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Discovery of Potent, Selective, and Short-Acting Peptidic V2 Receptor Agonists.
Wiśniewski K, Qi S, Kraus J, Ly B, Srinivasan K, Tariga H, Croston G, La E, Wiśniewska H, Ortiz C, Laporte R, Rivière PJ, Neyer G, Hargrove DM, Schteingart CD. Wiśniewski K, et al. Among authors: wisniewska h. J Med Chem. 2019 May 23;62(10):4991-5005. doi: 10.1021/acs.jmedchem.9b00132. Epub 2019 May 7. J Med Chem. 2019. PMID: 31022340
New, potent, and selective peptidic oxytocin receptor agonists.
Wiśniewski K, Alagarsamy S, Galyean R, Tariga H, Thompson D, Ly B, Wiśniewska H, Qi S, Croston G, Laporte R, Rivière PJ, Schteingart CD. Wiśniewski K, et al. Among authors: wisniewska h. J Med Chem. 2014 Jun 26;57(12):5306-17. doi: 10.1021/jm500365s. Epub 2014 Jun 12. J Med Chem. 2014. PMID: 24874785
Pharmacological, Pharmacokinetic, Pharmacodynamic and Physicochemical Characterization of FE 205030: A Potent, Fast Acting, Injectable CGRP Receptor Antagonist for the Treatment of Acute Episodic Migraine.
Srinivasan K, Kozminski K, Zhang Y, Wisniewski K, Kohout T, Wisniewska H, Harris G, Lindstrom B, Hargrove D. Srinivasan K, et al. Among authors: wisniewska h. J Pharm Sci. 2022 Jan;111(1):247-261. doi: 10.1016/j.xphs.2021.06.034. Epub 2021 Jul 2. J Pharm Sci. 2022. PMID: 34217775
Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome.
Hargrove DM, Alagarsamy S, Croston G, Laporte R, Qi S, Srinivasan K, Sueiras-Diaz J, Wiśniewski K, Hartwig J, Lu M, Posch AP, Wiśniewska H, Schteingart CD, Rivière PJ, Dimitriadou V. Hargrove DM, et al. Among authors: wisniewska h. J Pharmacol Exp Ther. 2020 May;373(2):193-203. doi: 10.1124/jpet.119.262238. Epub 2020 Feb 19. J Pharmacol Exp Ther. 2020. PMID: 32075870
New, potent, selective, and short-acting peptidic V1a receptor agonists.
Wisniewski K, Galyean R, Tariga H, Alagarsamy S, Croston G, Heitzmann J, Kohan A, Wisniewska H, Laporte R, Rivière PJ, Schteingart CD. Wisniewski K, et al. Among authors: wisniewska h. J Med Chem. 2011 Jul 14;54(13):4388-98. doi: 10.1021/jm200278m. Epub 2011 Jun 20. J Med Chem. 2011. PMID: 21688787
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.
Wiśniewski K, Sueiras-Diaz J, Jiang G, Galyean R, Lu M, Thompson D, Wang YC, Croston G, Posch A, Hargrove DM, Wiśniewska H, Laporte R, Dwyer JJ, Qi S, Srinivasan K, Hartwig J, Ferdyan N, Mares M, Kraus J, Alagarsamy S, Rivière PJ, Schteingart CD. Wiśniewski K, et al. Among authors: wisniewska h. J Med Chem. 2016 Apr 14;59(7):3129-39. doi: 10.1021/acs.jmedchem.5b01909. Epub 2016 Mar 25. J Med Chem. 2016. PMID: 26986178
40 results